952748-39-9 Usage
Uses
Used in Pharmaceutical Industry:
3-Bromo-pyrrolidine hydrochloride is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique structure allows for the creation of a range of medicinal compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-pyrrolidine hydrochloride is employed as a precursor in the synthesis of agrochemicals. Its properties enable the production of effective compounds for crop protection and enhancement of agricultural yields.
Used in Chemical Synthesis:
3-Bromo-pyrrolidine hydrochloride is used as a reagent in the synthesis of heterocyclic compounds. Its presence as a halogenated compound facilitates the formation of diverse chemical structures, broadening the scope of possible applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 952748-39-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,2,7,4 and 8 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 952748-39:
(8*9)+(7*5)+(6*2)+(5*7)+(4*4)+(3*8)+(2*3)+(1*9)=209
209 % 10 = 9
So 952748-39-9 is a valid CAS Registry Number.
952748-39-9Relevant articles and documents
AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS
-
Page/Page column 139, (2008/06/13)
Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+,K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.
